Skip to main content
NIH funding notice RFA-AI-22-020

Development and Optimization of Next-Generation Immunological Assays to Support Influenza Clinical Studies and Trials (UH2/UH3 Clinical Trial Not Allowed)

Closed on July 1, 2022.

Posted
April 5, 2022
Close date
July 1, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,120,453 in first-year total cost, median $560,227.

Most frequent study sections

  1. Special Emphasis Panel[ZAI1 AWA-M (J1)]2

Most frequent institutions

  1. IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE1
  2. MESO SCALE DIAGNOSTICS, LLC1
Competing awards under RFA-AI-22-020 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023A Flexible High-Throughput Immunological Assay to Support Next-Generation Influenza Vaccine Studies1UH2AI176136-01SIGAL, GEORGE BMESO SCALE DIAGNOSTICS, LLC, MD$842,062ZAI1
2023Immunity in the Nose to inFLUENza: Correlates of Efficacy (INFLUENCE)1UH2AI176172-01THWAITES, RYANIMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE$278,391ZAI1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.